Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction

Stephanie C Knüpfer, Martina D Liechti, Livio Mordasini, Dominik Abt, Daniel S Engeler, Jens Wöllner, Jürgen Pannek, Bernhard Kiss, Fiona C Burkhard, Marc P Schneider, Elena Miramontes, Alfons G Kessels, Lucas M Bachmann, Thomas M Kessler, Stephanie C Knüpfer, Martina D Liechti, Livio Mordasini, Dominik Abt, Daniel S Engeler, Jens Wöllner, Jürgen Pannek, Bernhard Kiss, Fiona C Burkhard, Marc P Schneider, Elena Miramontes, Alfons G Kessels, Lucas M Bachmann, Thomas M Kessler

Abstract

Background: Sacral neuromodulation has become a well-established and widely accepted treatment for refractory non-neurogenic lower urinary tract dysfunction, but its value in patients with a neurological cause is unclear. Although there is evidence indicating that sacral neuromodulation may be effective and safe for treating neurogenic lower urinary tract dysfunction, the number of investigated patients is low and there is a lack of randomized controlled trials.

Methods and design: This study is a prospective, randomized, placebo-controlled, double-blind multicenter trial including 4 sacral neuromodulation referral centers in Switzerland. Patients with refractory neurogenic lower urinary tract dysfunction are enrolled. After minimally invasive bilateral tined lead placement into the sacral foramina S3 and/or S4, patients undergo prolonged sacral neuromodulation testing for 3-6 weeks. In case of successful (defined as improvement of at least 50% in key bladder diary variables (i.e. number of voids and/or number of leakages, post void residual) compared to baseline values) prolonged sacral neuromodulation testing, the neuromodulator is implanted in the upper buttock. After a 2 months post-implantation phase when the neuromodulator is turned ON to optimize the effectiveness of neuromodulation using sub-sensory threshold stimulation, the patients are randomized in a 1:1 allocation in sacral neuromodulation ON or OFF. At the end of the 2 months double-blind sacral neuromodulation phase, the patients have a neuro-urological re-evaluation, unblinding takes place, and the neuromodulator is turned ON in all patients. The primary outcome measure is success of sacral neuromodulation, secondary outcome measures are adverse events, urodynamic parameters, questionnaires, and costs of sacral neuromodulation.

Discussion: It is of utmost importance to know whether the minimally invasive and completely reversible sacral neuromodulation would be a valuable treatment option for patients with refractory neurogenic lower urinary tract dysfunction. If this type of treatment is effective in the neurological population, it would revolutionize the management of neurogenic lower urinary tract dysfunction.

Trial registration number: http://www.clinicaltrials.gov; Identifier: NCT02165774.

Figures

Figure 1
Figure 1
Flowchart of the sacral neuromodulation (SNM) trial. SNM: sacral neuromodulation.

References

    1. Wöllner J, Hampel C, Kessler TM. Surgery illustrated - surgical atlas sacral neuromodulation. BJU Int. 2012;110(1):146–159.
    1. Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol. 2006;175(3 Pt 1):835–841.
    1. Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M, Chancellor MB, Richard F, Denys P. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol. 2000;164(5):1476–1480.
    1. Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev. 2009;2 CD004202.
    1. Kessler TM, Buchser E, Meyer S, Engeler DS, Al-Khodairy AW, Bersch U, Iselin CE, Roche B, Schmid DM, Schurch B, Zrehen S, Burkhard FC. Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland. Eur Urol. 2007;51(5):1357–1363.
    1. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama a Nijholt AA, Siegel S, Jonas U, Fowler CJ, Fall M, Gajewski JB, Hassouna MM, Cappellano F, Elhilali MM, Milam DF, Das AK, Dijkema HE, van den Hombergh U. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178(5):2029–2034.
    1. Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, Cottenden A, Davila W, de Ridder D, Dmochowski R, Drake M, Dubeau C, Fry C, Hanno P, Smith JH, Herschorn S, Hosker G, Kelleher C, Koelbl H, Khoury S, Madoff R, Milsom I, Moore K, Newman D, Nitti V, Norton C, Nygaard I, Payne C, Smith A, Staskin D. et al.Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213–240.
    1. Wallace PA, Lane FL, Noblett KL. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol. 2007;197(1):96. e91-95.
    1. Kessler TM, La Framboise D, Trelle S, Fowler CJ, Kiss G, Pannek J, Schurch B, Sievert KD, Engeler DS. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58(6):865–874.
    1. Kriston L, Gunzler C, Rohde A, Berner MM. Is one question enough to detect female sexual dysfunctions? A diagnostic accuracy study in 6,194 women. J Sex Med. 2010;7(5):1831–1841.
    1. Kriston L, Gunzler C, Harms A, Berner M. Confirmatory factor analysis of the German version of the international index of erectile function (IIEF): a comparison of four models. J Sex Med. 2008;5(1):92–99.
    1. Costa P, Perrouin-Verbe B, Colvez A, Didier J, Marquis P, Marrel A, Amarenco G, Espirac B, Leriche A. Quality of life in spinal cord injury patients with urinary difficulties. Development and validation of qualiveen. Eur Urol. 2001;39(1):107–113.
    1. Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194.
    1. International conference on harmonisation. Good clinical practice guideline. 1996. [ ]
    1. Swiss Academy of Medical Sciences. Guideline - Concerning scientific research involving human beings. 2009. [ ]
    1. The Federal Authorities of the Swiss Confederation. Bundesgesetz über den Datenschutz (DSG) vom 19. Juni 1992. 1992. [ ]
    1. Pannek J, Blok B, Castro-Diaz D, Del Popolo G, Groen J, Karsenty G, Kessler TM, Kramer G, Stöhrer M. EAU guidelines on neuro-urology. 2014. [ ]
    1. Wöllner J, Kessler TM. Botulinum toxin injections into the detrusor. BJU Int. 2011;108(9):1528–1537.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner